Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland

Hdl Handle:
http://hdl.handle.net/10147/579887
Title:
Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland
Authors:
Linnane, Barry; Kiernan, Miranda G; O’Connell, Nuala H; Kearse, Linda; Dunne, Colum P
Citation:
Multidisciplinary Respiratory Medicine. 2015 Oct 15;10(1):32
Issue Date:
15-Oct-2015
URI:
http://dx.doi.org/10.1186/s40248-015-0029-9; http://hdl.handle.net/10147/579887
Abstract:
Abstract Rationale There is limited evidence supporting the routine use of palivizumab in paediatric cystic fibrosis (CF) patients to reduce respiratory syncytial virus (RSV) infection and related hospitalisation. Despite this, anti-RSV prophylaxis is increasingly common. This is the first report from Ireland regarding palivizumab outcomes for children with CF, under 2 years old, despite the greatest prevalence of CF globally. Methods An audit was performed at a tertiary hospital in Ireland’s mid-West to document all children with CF, <24 months old, who received palivizumab over a five year period and comparision made with all eligible children for the prior five year period who had not received the product (also CF patients). Palivizumab was administered to both cohorts in their first year of life. Hospitalisation rates were compared using Fisher’s exact test. Incidence of RSV and Pseudomonas aeruginosa infection was recorded. Results A total of 19 patients who received palivizumab were included in the study; comparision was made with a retrospective control group of 30 patients. Prophylactic palivizumab did not prevent hospitalisation for 10/19 patients, 3 of whom were affected by RSV. This was significantly greater than in the control group, where no hospitalisations were recorded (p < 0.0001). P. aeruginosa was isolated in one case from the study cohort, while no P. aeruginosa was detected in the control group. Conclusions This study, the first of its kind from Ireland where CF prevalence is highest, does not provide unequivocal support for prophylactic use of palivizumab in CF patients under 2 years. Despite being derived from a small sample size, based on these data and complementary clinical observation, we have discontinued such prophylaxis. However, should reported incidence of RSV-related hospitalisation increase, there is scientific plausibility for appropriately powered, randomised, controlled trials of palivizumab.
Language:
en
Keywords:
CYSCTIC FIBROSIS; RESPIRATORY DISORDER

Full metadata record

DC FieldValue Language
dc.contributor.authorLinnane, Barryen
dc.contributor.authorKiernan, Miranda Gen
dc.contributor.authorO’Connell, Nuala Hen
dc.contributor.authorKearse, Lindaen
dc.contributor.authorDunne, Colum Pen
dc.date.accessioned2015-10-19T10:44:26Zen
dc.date.available2015-10-19T10:44:26Zen
dc.date.issued2015-10-15en
dc.identifier.citationMultidisciplinary Respiratory Medicine. 2015 Oct 15;10(1):32en
dc.identifier.urihttp://dx.doi.org/10.1186/s40248-015-0029-9en
dc.identifier.urihttp://hdl.handle.net/10147/579887en
dc.description.abstractAbstract Rationale There is limited evidence supporting the routine use of palivizumab in paediatric cystic fibrosis (CF) patients to reduce respiratory syncytial virus (RSV) infection and related hospitalisation. Despite this, anti-RSV prophylaxis is increasingly common. This is the first report from Ireland regarding palivizumab outcomes for children with CF, under 2 years old, despite the greatest prevalence of CF globally. Methods An audit was performed at a tertiary hospital in Ireland’s mid-West to document all children with CF, <24 months old, who received palivizumab over a five year period and comparision made with all eligible children for the prior five year period who had not received the product (also CF patients). Palivizumab was administered to both cohorts in their first year of life. Hospitalisation rates were compared using Fisher’s exact test. Incidence of RSV and Pseudomonas aeruginosa infection was recorded. Results A total of 19 patients who received palivizumab were included in the study; comparision was made with a retrospective control group of 30 patients. Prophylactic palivizumab did not prevent hospitalisation for 10/19 patients, 3 of whom were affected by RSV. This was significantly greater than in the control group, where no hospitalisations were recorded (p < 0.0001). P. aeruginosa was isolated in one case from the study cohort, while no P. aeruginosa was detected in the control group. Conclusions This study, the first of its kind from Ireland where CF prevalence is highest, does not provide unequivocal support for prophylactic use of palivizumab in CF patients under 2 years. Despite being derived from a small sample size, based on these data and complementary clinical observation, we have discontinued such prophylaxis. However, should reported incidence of RSV-related hospitalisation increase, there is scientific plausibility for appropriately powered, randomised, controlled trials of palivizumab.en
dc.language.isoenen
dc.subjectCYSCTIC FIBROSISen
dc.subjectRESPIRATORY DISORDERen
dc.titleAnti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Irelanden
dc.language.rfc3066enen
dc.rights.holderLinnane et al.en
dc.date.updated2015-10-15T06:02:48Zen
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.